The company is using an adenovirus vector modified to carry the cytosine deaminase gene, which expresses an enzyme that converts an antifungal agent into an antitumor agent at the site of expression. * HemaSure Inc., of Marlborough, Mass., acquired the plasma pharmaceutical business of Bagsvaerd, Denmark-based Novo Nordisk A/S. Raw materials will be paid for in cash or stock worth $1.8 million...NTC plans to make the technology available to companies on a non-exclusive basis. * OncoGenetics Inc

The company plans to discuss Phase III trial plans with the FDA. * GelTex Pharmaceuticals Inc., of Waltham, Mass., proposed a public offering of 2.5 million shares at $22.75 each...Each partner retains rights to technology contributed and they have co-exclusive rights to data generated during the partnership. * ImmunoGen Inc., of Cambridge, Mass., said data published in Blood showed its lead product, Oncolysin B, overcomes and eliminates multidrug resistance in tumors...Insmed is developing products

Privately held Synteni was formed in 1994 to commercialize the technology under a license from Stanford University. * T Cell Sciences Inc., of Needham, Mass., licensed rights to portions of its complement receptor 1 technology to CytoTherapeutics Inc., of Providence, R.I., for use in CytoTherapeutics' cell-based products for delivery of substances to the central nervous system...CytoTherapeutics has non-exclusive rights to use CR1 in encapsulated-cell products

* Sequus Pharmaceuticals Inc., of Menlo Park, Calif., said Amphocil, which is a combination of the anti-fungal amphotericin B and the company's lipid-based drug delivery system, was cleared for marketing in Sweden as a second-line treatment for systemic mycoses. Amphocil is approved in 10 countries outside the U.S. and is under review by the FDA. * U.S. Bioscience Inc., of West Conshohocken, Pa., said stockholders approved a one-for-two reverse split of the company's stock. (c) 1997 American

Terms were not disclosed. * Genetrix Inc., of Phoenix, a genetic testing laboratory, voted in favor of allowing Genzyme Corp., of Cambridge, Mass., to acquire it for $36.7 million in Genzyme stock...Oncogene Science also sold 500,000 shares to BioChem Pharma Inc., of Laval, Quebec, lifting the amount of the recent financing to about $30.6 million. * Sequus Pharmaceuticals Inc., of Menlo Park, Calif., said Amphocil, which is a combination of the anti-fungal amphotericin B and the company's lipid

Additional analysis of the findings is being conducted to determine if some groups of patients benefited from the vaccine more than others...Oncogene Science also sold 500,000 shares to BioChem Pharma Inc., of Laval, Quebec, lifting the amount of the recent financing to about $30.6 million. * Sequus Pharmaceuticals Inc., of Menlo Park, Calif., said Amphocil, which is a combination of the anti-fungal amphotericin B and the company's lipid-based drug delivery system, was cleared for marketing in

MedImmune will pay license fees, make milestone payments and contribute royalties to Rockefeller in return for rights to use genes identified by the university's researchers. * Neoprobe Corp., of Dublin, Ohio, entered an agreement with Peptor Ltd., of Israel, to form a joint venture for development of radiolabeled forms of Peptor's peptide analogues for detection and treatment of cancer

MedImmune will pay license fees, make milestone payments and contribute royalties to Rockefeller in return for rights to use genes identified by the university's researchers. * Neoprobe Corp., of Dublin, Ohio, entered an agreement with Peptor Ltd., of Israel, to form a joint venture for development of radiolabeled forms of Peptor's peptide analogues for detection and treatment of cancer

and Mexico to open soon. * IMRE Corp., now of San Diego, settled a patent infringement claim regarding the Prosorba column...Also, IMRE said it received stockholder approval to change its name to Cypress Bioscience Inc. * Neomecs Inc., of Minneapolis, received a $750,000 small business innovation research grant from the National Center for Human Genome Research for a continuing study aimed at increasing the sensitivity and usefulness of DNA probes in diagnostic and research applications

Protein A is used to purify monoclonal antibodies and the Allegro unit provides preclinical and Phase I/II testing materials. * Seragen Inc., of Hopkinton, Mass., licensed patents to Sandoz Ltd., of Basel, Switzerland, covering monoclonal antibodies to the interleukin-2 receptor for treatment of organ transplant rejection and other immune system disorders

Astra Merck is a joint venture between Merck & Co., of Whitehouse Station, N.J., and Astra AB, of Sodert lje, Sweden. * Houghten Pharmaceuticals Inc., of San Diego, added another $3.9 million to its March 29, 1996, initial public offering (IPO) when underwriters Dillon, Read & Co., Hambrecht & Quist LLC and Salomon Brothers, all of New York, exercised overallotment options for the purchase of 495,000 shares...and UBS Securities LLC, all of New York, exercised overallotment options to buy 412,500

The company plans to launch five trials this year, including two Phase III studies of GMK, a therapeutic vaccine for melanoma. * Sequana Therapeutics Inc., of La Jolla, Calif., and Aurora Biosciences Corp., of La Jolla, entered into a three-year agreement in the area of functional genomics...Sequana gets exclusive access to Aurora's technologies for positionally cloned genes, as well as preferential access to novel mammalian cell-based screening services. * Sequus Pharmaceuticals Inc., of Menlo

The company plans to launch five trials this year, including two Phase III studies of GMK, a therapeutic vaccine for melanoma...Sequana gets exclusive access to Aurora's technologies for positionally cloned genes, as well as preferential access to novel mammalian cell-based screening services

The agreement allows Amersham to file a supplemental new drug application with the FDA, which is planned later this year...Matritech Inc., of Newton, Mass., said its NMP22 Test Kit for detection of bladder cancer identified six of six patients who went on to develop the invasive form of the disease...Metra Biosystems Inc., of Mountain View, Calif., registered to sell 2.3 million shares in a public offering

In June 1995 Monsanto agreed to acquire 49.9 percent of Calgene in a deal valued at $200 million. (See BioWorld Today, June 29, 1995, p. 1.) (c) 1997 American Health Consultants

Biogen is seeking a partner to continue development. * NeXstar Pharmaceuticals Inc., of Boulder, Colo., got approval to market DaunoXome as a primary therapy for AIDS-related Kaposi's sarcoma in Germany, the Netherlands, Finland and Norway. * Emisphere Technologies Inc., of Hawthorne, N.Y., filed an investigational new drug application to conduct a Phase I study evaluating its proprietary technology for the oral delivery of heparin...Gensia now has approval to market the system, designed for use

Aronex Pharmaceuticals Inc., of The Woodlands, Texas, said it will expand the clinical program for the HIV inhibitor, an oligonucleotide called AR177, to include a Phase I trial with multiple doses...Van Kasper & Co., of San Francisco, managed the offering. * IMRE Corp., of Seattle, regained marketing rights to the Prosorba column from Baxter Healthcare Corp., of Deerfield, Ill. * Incyte Pharmaceuticals Inc., of Palo Alto, Calif., reached an agreement with GeneTrace Systems Inc., of Menlo Park

The product has shown efficacy in preclinical models of inflammation. * Immunogen Inc., of Cambridge, Mass., plans to issue $5 million of convertible debentures to an undisclosed investor...A portion of the funds will be used to complete a European plant in Edinburgh, Scotland, where the natural interferon product Omniferon will be manufactured. (c) 1997 American Health Consultants

to expand the approved indications for Abelcet, a lipid-based formulation of amphotericin B, to include first-line treatment of severe systemic invasive candidiasis. * Unimed Pharmaceuticals Inc., of Buffalo Grove, Ill., completed enrollment in a Phase II trial of nitazoxanide (NXT) for cryptosporidiosis in AIDS patients...The trial is expected to conclude by the end of June 1996